#Israel #Petach Tikva #Medison #Shay Tamari #Tali Mirsky

Medison Strengthens Global Leadership Team

In a move that underscores its commitment to expanding global operations, Medison has announced the appointment of Shay Tamari as Chief Business Officer (CBO) and Tali Mirsky as Chief Legal and Compliance Officer (CLCO). These strategic hires are designed to enhance Medison's capabilities in delivering breakthrough therapies to underserved markets.

Medison has established itself as a pioneer with its unified global commercialization platform, which is designed to streamline the launch of innovative therapies in regions outside of the U.S., Western Europe, and Japan. By leveraging an end-to-end model, the company aims to assist biotech firms in planning and optimizing their products for a global audience. The recent changes in the leadership team are a part of Medison's broader strategy to scale its operations and strengthen relationships with global biotech partners.

Shay Tamari, with over 20 years of experience in the pharmaceutical sector, joins Medison to spearhead global corporate development. He has a notable background that includes a decade at Pfizer, and he possesses substantial insights into the U.S. biotech ecosystem. His focus will be on creating long-term growth opportunities through strategic partnerships, all while promoting the reach of Medison's innovative platform. Operating from the U.S. allows him to maintain crucial connections with biotech hubs and industry leaders, thus driving Medison's initiatives forward.

On the other hand, Tali Mirsky brings over 25 years of legal and compliance expertise, gained through her extensive career in both private and public companies, most recently at NICE. Her vast experience in global transactions and corporate governance complements Medison's mission to advance its platform's integrity and compliance as it expands into diverse international markets. Tali's role will be vital in ensuring that Medison operates under high standards of ethics and governance, reinforcing trust with partners and stakeholders alike.

Gil Gurfinkel, CEO of Medison, expressed enthusiasm about the new appointments, stating, “We are excited to welcome Shay and Tali to Medison's leadership team. Their experience in leading public companies and their deep industry expertise will be instrumental as we continue to scale our operations and bring breakthrough therapies to patients in underserved markets around the world.”

Meir Jakobsohn, Founder and Executive Chairman, acknowledged the importance of strengthening leadership capacity, adding that the company is dedicated to making breakthrough therapies accessible to all patients, regardless of their geographical location. The leadership's commitment to these values aligns with Medison's mission of transforming global biotech commercialization.

Shay Tamari conveyed his excitement about joining at such a pivotal moment, stating, “Medison's unique platform and vision for global biotech commercialization are compelling. I look forward to working closely with the team to deepen our partnerships and expand access to breakthrough therapies for patients.” Likewise, Tali Mirsky reflected on the importance of compliance and operational excellence, stating her eagerness to support the next phase of growth.

With these strategic appointments, Medison is poised to enhance its ability to expedite the availability of innovative therapies to more patients worldwide, delivering significant impact in regions that often lack access to modern medical solutions. Medison's platform not only aims to support biotech partners but also represents a commitment to elevating healthcare standards globally, especially for patients battling severe and rare diseases.

About Medison

Medison is charting a new course in global biotech commercialization, striving to change lives through its pioneering efforts. As a singular global commercialization platform, Medison collaborates with biotech firms to improve the availability of breakthrough therapies worldwide, particularly for patients with rare and severe conditions. The company's unique approach engages operational, medical, and commercial capabilities across various regions, allowing biotech innovators to scale their efforts effectively while ensuring localized impact. By fostering a culture of creativity and expertise, Medison aspires to democratize access to vital healthcare solutions, driven by the belief that every patient deserves the chance for a fulfilling life, irrespective of their location.